Flush with cash from their GLP-1 franchises, Eli Lilly and Novo Holdings have become the most active participants in Series A biotech funding. They are leveraging their deep pockets to stimulate company formation and strategically branch into new therapeutic areas, shaping the next wave of innovation.

When asked about the next trillion-dollar healthcare company, venture capitalist Bob Nelsen stated he couldn't name one. He believes Eli Lilly's market dominance is so strong that it is more probable for them to double their valuation than for any other healthcare peer to reach that milestone first.

After reporting strong earnings and a positive forecast for its GLP-1 drugs, Eli Lilly's market capitalization increased by nearly $100 billion in a single trading day. This staggering gain, equivalent to the entire value of another large pharma company, highlights the immense investor confidence in its competitive position.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Eli Lilly's recent deal-making reveals an aggressive, multi-modal strategy. It secured an AI partnership for obesity (Nimbus), invested in an AI platform for oncology (InduPro), and spent $1.2B acquiring Ventix Biosciences for its oral inflammation pipeline, demonstrating a broad approach to securing leadership in its focus areas.

Despite their obesity drugs having similar clinical efficacy—both help patients lose 15-20% of body weight—Eli Lilly's market cap has skyrocketed while Novo Nordisk's has been flat. This massive valuation gap suggests investor narrative and perceived safety profiles are dramatically outweighing the fundamental product similarities.

The long-held belief that solving obesity would create immense wealth is now validated by Eli Lilly's $1T market cap, driven by its GLP-1 weight-loss drugs. This marks a significant shift, as the trillion-dollar club was previously dominated by tech and oil companies.

Within one week, Eli Lilly executed two massive deals: an $8.5B potential collaboration with Innovent for antibody therapeutics and a $2.4B acquisition of Orna Therapeutics for its circular RNA CAR-T platform. This signals an aggressive, multi-pronged strategy to dominate both established and next-generation therapeutic modalities.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.